2181.HK

Mabpharm Limited [2181.HK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

2181.HK Stock Summary

Earnings are expected to fall -100% next year

2181.HK has less than 1 year of cash runway

In the News

2181.HK Financial details

Company Rating

Neutral

Market Cap

1.86B

Income

-194.01M

Revenue

71.09M

Book val./share

0.07

Cash/share

0.01

Dividend

Dividend %

Employees

347

Optionable

Shortable

Yes

Earnings

27 Mar 2024

P/E

-8.07

Forward P/E

PEG

2.37

P/S

30.41

P/B

4.24

P/C

42.5

P/FCF

-9.34

Quick Ratio

0.26

Current Ratio

1.07

Debt / Equity

0.48

LT Debt / Equity

0.27

EPS (TTM)

-0.05

EPS next Y

EPS next Q

EPS this Y

-28.33%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

SMA20

SMA50

SMA100

Inst Own

Inst Trans

ROA

-23%

ROE

-42%

ROC

-0.28%

Gross Margin

73%

Oper. Margin

-365%

Profit Margin

-377%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.25-0.95

52W High

52W Low

RSI

Rel Volume

1.18

Avg Volume

37.42K

Volume

44K

Perf Week

-14.14%

Perf Month

-1.16%

Perf Quarter

Perf Half Y

-6.59%

Beta

0.782

Volatility

0.02%, 0.02%

Prev Close

-5.56%

Price

0.425

Change

-5.56%

2181.HK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0.02	0.01
Net income per share	-0.03	-0.06	-0.05	-0.07	-0.05
Operating cash flow per share	-0.02	-0.04	-0.04	-0.05	-0.01
Free cash flow per share	-0.04	-0.07	-0.08	-0.08	-0.04
Cash per share	0.05	0.2	0.12	0.02	0.01
Book value per share	0.06	0.28	0.21	0.15	0.1
Tangible book value per share	0.05	0.28	0.21	0.15	0.1
Share holders equity per share	0.06	0.28	0.21	0.15	0.1
Interest debt per share	0.03	0.03	0.01	0.01	0.03
Market cap	4.38B	3.9B	3.64B	3.37B	1.58B
Enterprise value	4.29B	3.42B	3.2B	3.33B	1.68B
P/E ratio	-35.06	-18.57	-19.32	-11.44	-7.52
Price to sales ratio	0	277.4	0	40.61	28.33
POCF ratio	-70.77	-28.58	-24.75	-16.87	-27.85
PFCF ratio	-28.66	-15.6	-10.58	-9.67	-8.7
P/B Ratio	17.55	3.71	4.13	5.59	3.95
PTB ratio	17.55	3.71	4.13	5.59	3.95
EV to sales	0	243.07	0	40.18	29.99
Enterprise value over EBITDA	-31.42	-19.82	-20.47	-13.57	-11.01
EV to operating cash flow	-69.26	-25.04	-21.73	-16.69	-29.48
EV to free cash flow	-28.05	-13.67	-9.29	-9.57	-9.21
Earnings yield	-0.03	-0.05	-0.05	-0.09	-0.13
Free cash flow yield	-0.03	-0.06	-0.09	-0.1	-0.11
Debt to equity	0.42	0.1	0.05	0.08	0.32
Debt to assets	0.22	0.08	0.03	0.05	0.14
Net debt to EBITDA	0.68	2.8	2.84	0.15	-0.61
Current ratio	1.67	3.53	2.81	1.05	1.07
Interest coverage	-33.05	-25.32	-45.84	-120.38	-28.36
Income quality	0.41	0.67	0.8	0.68	0.27
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	6.43	0	0.26	0.39
Research and developement to revenue	0	9.53	0	3.18	2.65
Intangibles to total assets	0.08	0	0	0	0
Capex to operating cash flow	1.47	0.83	1.34	0.75	2.2
Capex to revenue	0	-8.07	0	-1.79	-2.24
Capex to depreciation	-7.76	-5.12	-8.08	-3.39	-2.43
Stock based compensation to revenue	0	0.98	0	0.15	0.17
Graham number	0.2	0.59	0.47	0.48	0.33
ROIC	-0.41	-0.17	-0.19	-0.42	-0.36
Return on tangible assets	-0.29	-0.15	-0.16	-0.33	-0.23
Graham Net	0	0.11	0.05	-0.05	-0.1
Working capital	104.3M	684.81M	366.5M	12.77M	12.72M
Tangible asset value	211.46M	1.05B	881.49M	601.98M	400.94M
Net current asset value	37.1M	612.37M	287.57M	-50.15M	-315.46M
Invested capital	0.42	0.1	0.05	0.08	0.32
Average receivables	0	0	0.5	396.5K	5.16M
Average payables	6.38M	8.04M	4.43M	32.28M	38.34M
Average inventory	31.94M	24.89M	27.83M	43.32M	77M
Days sales outstanding	0	0	0	3.49	62.22
Days payables outstanding	0	0	0	1.31K	393.75
Days of inventory on hand	0	0	0	1.16K	2.39K
Receivables turnover	0	0	0	104.52	5.87
Payables turnover	0	0	0	0.28	0.93
Inventory turnover	0	0	0	0.32	0.15
ROE	-0.5	-0.2	-0.21	-0.49	-0.53
Capex per share	-0.02	-0.03	-0.05	-0.04	-0.03

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0.01	0.01
Net income per share	-0.02	-0.01	-0.01	-0.01	-0.01
Operating cash flow per share	0	-0.01	-0.01	0	0
Free cash flow per share	-0.01	-0.01	-0.01	0	0
Cash per share	0.02	0.01	0.01	0.01	0.01
Book value per share	0.13	0.1	0.1	0.07	0.07
Tangible book value per share	0.13	0.1	0.1	0.07	0.07
Share holders equity per share	0.13	0.1	0.1	0.07	0.07
Interest debt per share	0.03	0.03	0.03	0.03	0.04
Market cap	2.03B	1.29B	1.58B	2.67B	1.89B
Enterprise value	2.07B	1.26B	1.68B	2.65B	2.01B
P/E ratio	-8.68	-6.86	-8.43	-13.34	-9.43
Price to sales ratio	140.55	95.28	117.05	121.23	85.72
POCF ratio	-367.07	-56.27	-69.13	-159.14	-112.52
PFCF ratio	-37.16	-35.38	-43.46	-131.31	-92.84
P/B Ratio	4.13	3.22	3.95	8.7	6.15
PTB ratio	4.13	3.22	3.95	8.7	6.15
EV to sales	143.76	92.8	123.91	120.18	91.37
Enterprise value over EBITDA	-40.53	-30.88	-41.23	-72.44	-55.07
EV to operating cash flow	-375.48	-54.8	-73.17	-157.76	-119.93
EV to free cash flow	-38.01	-34.46	-46.01	-130.17	-98.96
Earnings yield	-0.03	-0.04	-0.03	-0.02	-0.03
Free cash flow yield	-0.03	-0.03	-0.02	-0.01	-0.01
Debt to equity	0.26	0.32	0.32	0.34	0.48
Debt to assets	0.14	0.14	0.14	0.11	0.16
Net debt to EBITDA	-0.91	0.83	-2.28	0.63	-3.4
Current ratio	1.01	1.07	1.07	0.83	0.83
Interest coverage	0	0	-11.23	0	-9.49
Income quality	0.09	0.49	0.49	0.34	0.34
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.66	1.58	1.58	1.07	1.07
Research and developement to revenue	2.7	2.58	2.58	1.35	1.35
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	8.88	0.59	0.59	0.21	0.21
Capex to revenue	-3.4	-1	-1	-0.16	-0.16
Capex to depreciation	-3.84	-1.04	-1.04	-0.26	-0.26
Stock based compensation to revenue	0.21	0.14	0.14	0.13	0.13
Graham number	0.21	0.16	0.16	0.14	0.14
ROIC	-0.09	-0.1	-0.09	-0.12	-0.1
Return on tangible assets	-0.06	-0.05	-0.05	-0.06	-0.06
Graham Net	-0.08	-0.1	-0.1	-0.12	-0.12
Working capital	1.21M	12.72M	12.72M	-43.67M	-43.67M
Tangible asset value	491.13M	400.94M	400.94M	306.62M	306.62M
Net current asset value	-222.65M	-315.46M	-315.46M	-386.13M	-386.13M
Invested capital	0.26	0.32	0.32	0.34	0.48
Average receivables	0	6.69M	9.53M	19.27M	29.01M
Average payables	0	22.82M	16.68M	16.66M	16.55M
Average inventory	0	90.58M	100.8M	102.02M	103.24M
Days sales outstanding	24.02	63.38	63.38	118.62	118.62
Days payables outstanding	470.18	698.42	690.92	486.04	475.03
Days of inventory on hand	1.31K	4.2K	4.2K	3K	3K
Receivables turnover	3.75	1.42	1.42	0.76	0.76
Payables turnover	0.19	0.13	0.13	0.19	0.19
Inventory turnover	0.07	0.02	0.02	0.03	0.03
ROE	-0.12	-0.12	-0.12	-0.16	-0.16
Capex per share	-0.01	0	0	0	0

2181.HK Frequently Asked Questions

What is Mabpharm Limited stock symbol ?

Mabpharm Limited is a CN stock and trading under the symbol 2181.HK

What is Mabpharm Limited stock quote today ?

Mabpharm Limited stock price is $0.425 today.

Is Mabpharm Limited stock public?

Yes, Mabpharm Limited is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 37.42K
Market Capitalization 1.86B
Employee 347
CEO Dr. Hao Wang
Headquarters Taizhou,CN
IPO Date 2019-05-31
Website https://www.mabpharm.cn

Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for allergic diseases, cancers, and autoimmune diseases in China. Its products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-IgE monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis; and CMAB807 for osteoporosis indications. The company is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB809 that is in Phase I clinical trial for the treatment of HER2 overexpressing breast cancer and metastatic gastric cancer. In addition, its products under the pre-clinical stage include CMAB810 for the treatment of breast cancer; CMAB816 for the treatment of periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; CMAB017 for the treatment of KRAS wild-type colorectal cancer; CMAB015, a biosimilar candidate for secukinumab to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis; and CMAB022 for the treatment of inflammatory diseases. The company also involved in research and development, technical consulting, technology transfer, and technical services of biological products, diagnostic reagents, chemical biological reagents, and drugs. The company was incorporated in 2018 and is headquartered in Taizhou, the People's Republic of China.